




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>3</sup> :  A61N 1/32	A1	(11) International Publication Number: WO 85/ 01213 (43) International Publication Date: 28 March 1985 (28.03.85)
(21) International Application Number: PCT/US84/01445 (22) International Filing Date: 11 September 1984 (11.09.84) (31) Priority Application Number: 531,955 (32) Priority Date: 14 September 1983 (14.09.83) (33) Priority Country: US  (71)(72) Applicant and Inventor: ZABARA, Jacob [US/US]; 317 Hedgerow Lane, Wyncote, PA 19095 (US).  (74) Agents: LEHRER, Norman, E. et al.; Duffield & Leh- rer, Suite 218, 409 Route 70 East, Cherry Hill, NJ 08034 (US).  (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (European patent), FR (European patent), GB (European pa- tent), JP, LU (European patent), NL (European pa- tent), SE (European patent).		Published <i>With international search report.</i>

(54) Title: NEUROCYBERNETIC PROSTHESIS



## (57) Abstract

A neurocybernetic prosthesis for controlling or preventing epileptic seizures and other motor disorders includes a pulse generator (10) which generates electrical pulses having a frequency of between 30 and 80 cycles per second, a pulse duration of between .3 and 1 millisecond and a constant current of between 1 and 10 milliamperes. The generator (10) is enclosed in an epoxy-titanium shell and is implanted in the body, preferably in the axilla (66). Electrode leads (18, 20) pass from the generator (10) through a subcutaneous tunnel and terminate in an electrode patch (62) on the vagus nerve (26). Provisions are made for varying the electrical signal from the generator (10) after it has been implanted to 'tune' the same to the patient. The prosthesis may be designed to be turned on manually when the patient senses the imminence of a convulsion. Alternatively, sensors (48, 50) may be provided for determining changes in the values of state parameters such as electroencephalographic waves which precede a convulsion. The pulse generator (10) can then be turned on automatically in response to sensors (48, 50).

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

Description

## NEUROCYBERNETIC PROSTHESIS

Technical Field

5 The present invention is directed toward a medical prosthesis and more particularly toward a medical prosthesis for alleviating or preventing epileptic seizures and other related clinical conditions of the nervous system such as spasticity.

Background Art

10 Certain diseases or malfunctions of the nervous system are associated with abnormal neural discharge patterns. Some of these are more or less continuous or chronic, such as is the case with Parkinsonism. Others may be discontinuous, characterized by threshold  
15 phenomena, such as in epilepsy. The time of onslaught of grand mal or petit mal seizures is often predictable by neural discharge monitoring or other means, even when the exact causal nature of the precipitating dysfunction is not understood.

20 It is recognized, however, and confirmed by experimentation, that the introduction of certain control signals of the proper configuration, intensity and duration can act as a means for discharging or modifying hyperactivity in the brain. The superposition  
25 of such corrective measures, whether by the generation of proper interference patterns overriding control pulses or cancelling signals, acts in a way to inhibit the normal progress of the seizure and may prevent it altogether. It is also possible that control signals  
30 of proper magnitudes when applied to associated neural tracts can cause neural activity to return to its normal state.

Corrective signals of this type can be generated by appropriate electrical pulses or waves applied



-2-

to neurons. Neurons produce electrochemical signals called action potentials which can be triggered by electronic devices.

5 The intent of the present invention is the im-  
plantation of a neurocybernetic prosthesis in the  
human for epileptic control. The operation of the  
prosthesis is based on the principle of augmenting  
inhibitory processes in the brain to control states  
of hypersynchronous neural discharge.

10 Currently, approximately seventy-five percent  
of epileptics are responsive in some degree to drugs,  
although undesirable side-effects may force discon-  
tinuance. Drug therapy necessitates a continual, gen-  
eral effect on brain cells and other tissues, not  
15 infrequently resulting in undesirable side effects  
whereas epilepsy constitutes an interrupted condition  
occurring at an approximate average of two convulsions  
per week. Unlike drug therapy, a neurocybernetic pros-  
thesis can be made operational just during the period  
20 of the convulsion by utilizing sensor feedback or  
manual control. Also, objective evaluation of drug  
effectiveness involves determination of chemical levels  
in the blood which is a very costly procedure. Since  
hyperactivity of the brain is the basis of many nervous  
25 system ailments such as Parkinson's disease, cerebral  
palsy, spasticity, motor disorders, etc., such a pros-  
thesis would also be useful for these chronic nervous  
illnesses.

An attempt had been made in the past to provide  
30 a neurocybernetic prosthesis for alleviating epilepsy  
and other disorders. It did not, however, meet with  
much success for several reasons. This prior attempt  
included a device which had to be implanted into the  
brain (cerebellum) thereby requiring expensive and  
35 extremely risky brain surgery. Furthermore, the im-  
planted device was found to produce tissue trauma  
in the cranium. It was found that there was a progres-



-3-

sive deterioration of cell bodies in the cerebellar cortex due to the electrical current and excessive regeneration of connective tissue.

#### Disclosure of Invention

5       The present invention is designed to obviate the need for brain surgery and the resulting tissue trauma caused thereby and to reduce or eliminate an epileptic's dependence on drugs. The prosthesis of this invention includes a miniature electronic integrated circuit whose output augments appropriate brain neural discharge to control convulsions or seizures. 10       The circuitry and battery pack are preferably enclosed in an epoxytitanium shell so that the entire device can be totally implanted, preferably in the axilla. 15       Electrode leads pass from the circuit through a subcutaneous tunnel formed toward the neck. The leads terminate in an electrode patch on the vagus nerve.

      The device can be operated either by sensor feedback or manual control and has the capability of regulating aberrant brain signals capable of initiating a convulsive disorder. The principle of design of the neurocybernetic device is based on augmenting central inhibitory processes to regulate the central excitatory state in order to prevent hypersynchronous activity leading to a convulsion. It, therefore, has 20       direct applicability to epilepsy and other nervous system illnesses where convulsions or convulsion-like states obtain. 25

#### Brief Description of Drawings

30       For the purpose of illustrating the invention, there are shown in the accompanying drawings forms which are presently preferred; it being understood that the invention is not intended to be limited to the precise arrangements and instrumentalities shown.

35       Figure 1 is a schematic representation of a totally implanted neurocybernetic prosthesis constructed



-4-

in accordance with the principles of the present invention and showing the manner in which the same is tuned;

Figure 2 is a schematic representation of a partially implanted neurocybernetic prosthesis;

5 Figure 3 is a schematic representation of a sensor-feedback system for automatically initiating the neurocybernetic prosthesis;

10 Figure 4 schematically illustrates the placement of an electrode patch on the vagus nerve and the relationship of the vagus nerve with adjacent structures, and

Figure 5 schematically represents the preferred placement of the pulse generator and electrode patch of the present invention in the human body.

15 Best Mode for Carrying Out the Invention

The present invention operates utilizing a principle called neurocybernetic spectral discrimination and works in the following way. Since, in general, nerves are of a microscopic diameter and are combined together in a nonhomogeneous mixture of diameters and functional properties, it is not presently possible to adequately control external current to selectively activate a specific group of nerves embedded within a relatively large number of other nerves. Spectral discrimination acts to overcome this fundamental problem by "tuning" the external current (electrical generator) to the electrochemical properties of the selected nerves.

20 The electrochemical properties utilized in the design of the discriminator are: action potential, conduction velocity, refractory period, threshold, resting membrane potential and synaptic transmission. In addition, there are two general properties of the brain called central excitatory state and hypersyn-  
35 chronicity which can be explained in the following manner.



-5-

All nerves can be divided into two functional types: excitatory and inhibitory. The spectral discriminator acts to selectively activate those inhibitory nerves which can prevent or block the epileptic seizure. In other words, these specific inhibitory nerves are embedded in a bundle or cable of nerve fibers of varied functions and properties. A bundle of such nerves may typically consist of 100,000 or more individual fibers and contain mixed excitatory and inhibitory characteristics. The purposeful design of the discriminator is to activate just those relatively few nerves which are inhibitory to the epileptic seizure.

Thus, it must be possible to "discriminate" those desired fibers within a broad spectrum of nerves. One reason that this is important is that if excitatory fibers are simultaneously activated with inhibitory fibers then the desired effect of inhibition on the seizure may be nullified. There is a balance of excitation and inhibition in the brain called the central excitatory state which is affected by specific electrochemical signals. Epilepsy is the increase of the central excitatory state to an abnormal level as based on a hypersynchronous discharge of neurons. A second reason for spectral discrimination is to prevent undesirable side-effects by activating other nerves unnecessarily.

There is a physiological basis for the effectiveness of the selected nerves in blocking or preventing epileptic seizures. The activation of these nerves produces an effect on the reticular system via synaptic transmission. The reticular system has been demonstrated to be important in whatever abnormality leads to epileptic seizures. The reticular system is a relatively large and inhomogeneously constituted structure extending from the hind-brain (medulla) to the mid-brain (thalamus) with neural connections to the cere-



bral cortex and spinal cord. It is not practical at present to directly electrically activate the reticular system because of its large extent and proximity to vital centers. Thus, it was important to discover  
5 what nerves might innervate the reticular system sufficiently to produce a significant effect on the reticular system; the net effect being to produce inhibition of epileptic seizures.

For the purpose of interfacing the prosthesis  
10 with the critical processes of the brain, inhibition can also be called by its comparable engineering term of negative feedback. Further, it is possible that the seizure originates due to a temporary lack or diminution of negative feedback from the reticular  
15 system to seizure sites in the brain. By acting on appropriately selected nerves, the prosthesis results in the replacement of this negative feedback and thus prevents the seizure.

The approach of spectral discrimination is to  
20 utilize the basic properties of conduction velocity, diameter, refractory period, threshold, membrane potential, action potential, after potentials, synchronization and synaptic transmission. Based on these properties, the parameters of the pulse generator are chosen  
25 in terms of frequency, duration of pulse wave, shape of wave, voltage or current and duration of pulse train. In addition, a time-dependent direct current polarization of the membrane can be utilized to produce a "gate" effect.

30 The "gate" effect is based upon the polarization characteristics of the neural membrane. The membrane potential across the neural membrane can be increased to a point where a block of conduction results. It is a method of separating relatively slower conducting  
35 fibers from faster conducting fibers. For example, when the nerve is activated, the action potentials of higher velocity (A) will lead the slower ones (C).





-7-

A "polarization" block on the nerve membrane will stop A and then the block is removed before C arrives so that the net result is that A, but not C, is prevented from continuing.

5        The next step is to determine the locus of action of the current generated by the spectral discriminator. This problem relates to the important area of interface between the electronic pulse generator and control  
10       interface should be of such a nature that the pulse generator is located external to the brain but at the same time the current be set in a compact and identifiable region of nerves so that the site of current is specific and reproducible from patient  
15       to patient; no cell bodies are located within the targeted area for current (due to possible production of cell deterioration by the current); and the nerves produce the desired effect on brain operations via sites of synaptic connection.

20       Analysis by spectral discrimination has demonstrated that the most desirable extra-cranial sites for all these effects are the cranial nerves. Specific cranial nerves have been determined to be optimum for beneficial effects on neurological problems. In  
25       particular, the vagus nerve is the optimum site for control of epileptic seizures.

      If the total spectrum of the nerve is not known, it is possible to activate all the nerve fibers by the spectral discriminator and record the response  
30       on an oscilloscope. From this total fiber spectrum, it is possible to determine the settings of the spectral discriminator to select the activation of the appropriate subset of nerves.

      Thus, it is possible to identify by the operation  
35       of the spectral discriminator those nerves which can produce the desired corrective signal. Spectral discrimination is not only a therapeutic prosthetic method



but it is also the method of analysis to determine nervous system sites for beneficial effects in neurological problems.

5 The present neurocybernetic prosthesis need be turned on only during the duration of a seizure. It can be turned on either manually (by the patient) or automatically by a sensor-feedback system. Many epileptics have sensory signs immediately preceding the convulsion called an aura. At the initiation of  
10 the aura, the patient will be able to turn on the device and prevent the seizure. On the other hand, the neurocybernetic prosthesis can include a sensor-feedback system to block the seizure automatically. This feedback system would include sensors specifically  
15 designed to determine relatively instantaneous changes in the values of state parameters, which precede eruption of the hypersynchronous activity. Such parameters might include electroencephalographic waves, respiration changes, heart rate changes, various auras or  
20 motor effects such as tics or myoclonic jerks. The prosthesis thereby can be activated by sensor feedback producing a signal which precedes convulsive hypersynchronous discharge.

One example of an electrical circuit for practicing the present invention is shown schematically  
25 in Figure 1. The circuit is comprised essentially of a pulse generator 10 which is capable of generating electrical pulses having a frequency of between 30 and 80 cycles per second, a pulse duration of between .3 and 1 millisecond and a constant current of between  
30 approximately 1 and 10 milliamperes. The frequency, pulse width and the voltage or current level of the output signal from the pulse generator can be varied by controls 12, 14 and 16. Electrode leads 18 and  
35 20 are connected to electrodes 22 and 24 which are applied to the vagus nerve 26 in a manner to be more fully described hereinafter.



-9-

In the preferred embodiment of the invention, the pulse generator 10 with its battery pack and other associated circuits are preferably intended to be fully implanted. For this reason, the generator is enclosed in an epoxy-titanium shell 28 (or similar bio-compatible material). As described above, the present invention operates utilizing the principle of neurocybernetic spectral discrimination. The prosthesis must, therefore, combine the desired current parameters to correspond to the specific properties (linear and non-linear) of the selected nerves. Thus, the command signal of the device is a function of the following specific nerve properties: refractory periods, conduction velocity, synchronization or desynchronization, threshold and brain inhibitory state. In a sense, the current parameters must be "tuned" to the specified nerve properties.

It is for the foregoing reason that the pulse generator 10 is provided with the means 12, 14 and 16 for varying the various current parameters of the pulse signal. The desired parameters are chosen by applying the electrodes 22 and 24 to the vagus nerve and varying the current parameters until the desired clinical effect is produced.

Since this "tuning" may have to be performed after the pulse generator is implanted, the present invention provides a means for varying the current parameters percutaneously. This is accomplished by a reed switch 30 associated with the implanted pulse generator 10 which is remotely controlled by electromagnet 32 and external programmer 34. The precise manner in which this is accomplished and the circuitry associated therewith is well known to those skilled in the art as the same technique has been widely used in connection with the "tuning" of cardiac pacemakers.

The device shown in Figure 1 is intended for full implantation. It is also possible to practice



-10-

the present invention with partial implantation. This is accomplished as shown in Figure 2 by the use of a receiver 36 including a coil 38 and diode 40. The receiver is enclosed in an epoxytitanium shell so that it can be implanted and is connected to the electrodes 22 and 24 on the vagus nerve through leads 18 and 20.

Located percutaneously is a pulse generator 42 which modulates the radio frequency transmitter 44 and delivers the radio frequency signal to antenna 46 which transmits the same to the receiver 36 when desired. It should be readily apparent that pulse generator 42 is also capable of being tuned so that the desired current parameters can be obtained. The pulse generator 42, transmitter 44 and antenna 46 could either be permanently worn on a person's body in the vicinity of the receiver 36 so that it need only be turned on when necessary or it may be separately carried in a person's pocket or the like and used whenever needed.

When the neurocybernetic prosthesis of the present invention is utilized for preventing epileptic seizures, it is only necessary for the current generator to be turned on immediately preceding a convulsion. Many epileptics have sensory signs immediately preceding the convulsion called an aura. At the initiation of the aura, the patient will be able to turn on the device to prevent the seizure through the use of a manually operated switch. Even with a fully implanted prosthesis, a momentary contact switch, magnetically operated reed switch or a number of other devices could be provided which could be activated from outside of the body.

It is also possible to provide the prosthesis with a sensor-feedback system to block the seizure automatically. An example of such a system is shown in Figure 3 and includes additional scalp electrodes



-11-

48 and 50 for measuring electroencephalographic waves. The output of the electrodes 48 and 50 is amplified by amplifier 52 and is then passed through filter 54 to level detector 56. When level detector 56 senses a significant and predetermined change in the electroencephalographic wave signal, it will automatically initiate the pulse generator 10 which will apply the required pulses to the electrodes 22 and 24 through runaway protection circuit 58 and voltage control circuit 60.

Although the sensing of electroencephalographic waves has been used above as an example for automatically turning on the neurocybernetic prosthesis, it should be apparent that other state parameters can be measured to provide a sensor-feedback system. Such other parameters might include respiration changes, heart rate changes, various auras or motor effects such as tics or myoclonic jerks. As a result, the prosthesis can be activated by sensor feedback producing a signal which precedes convulsive hypersynchronous discharge.

Figure 4 illustrates the placement of the electrodes on the vagus nerve and shows the relationship of the vagus with adjacent structures. The electrodes are shown as a single electrode patch 62 which is known per se. Electrode patch 62 includes both the positive and negative electrodes.

Although it is theoretically possible to place the electrode patch 62 or separate electrodes substantially anywhere along the length of the vagus nerve 26, minimal slowing of the heart rate is achieved by placing the same below the inferior cardiac nerve 64. The electrodes may be placed on or adjacent to the vagus. It is essential, however, that the negative electrode be proximal to the brain and the positive electrode be distal thereto. In certain instances, the positive electrode may be used as an indifferent electrode and be placed in a different part of the



-12-

body. For example, the case 26 of the implanted pulse generator 10 could, in some instances, be utilized as the positive electrode.

5 An electrode patch such as that shown in Figure 4 is the preferred embodiment. However, it should be readily apparent to those skilled in the art that various known electrodes could be utilized. The electrodes may be placed either in direct contact with the nerve or in indirect contact with the neural tissue. There is no indication that placement of state  
10 of the art electrodes on the nerve itself would have a deleterious effect unless silver electrodes are utilized.

As shown in Figure 5, the axilla or armpit 66  
15 is the preferred location for placement of the pulse generator 10. The axilla provides protection for the pulse generator while allowing freedom of movement and is in proximity to the electrode patch 62. A subcutaneous tunnel between the incision made to implant  
20 the electrode patch and the incision made for implanting the pulse generator can be made with a metal rod. A plastic tube can then be inserted in the tunnel through which the electrode leads 18 and 20 can pass without excessive traction.

25 The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and accordingly, reference should be made to the appended claims rather than to the foregoing specification as indicating the scope  
30 of the invention.



-13-

Claims

1. A method of controlling or preventing involuntary movements such as caused by epileptic seizures, cerebral palsy, Parkinson's disease, spasticity, motor disorders and the like comprising applying a pulsed electrical signal to the vagus nerve.
2. The method of Claim 1 wherein the electrical signal has a pulse frequency of approximately between 30 and 80 cycles per second and wherein each pulse has a duration of between .3 and 1 millisecond and substantially constant current of between approximately 1 and 10 milliamperes.
3. The method of Claim 1 wherein the signal is applied utilizing a plurality of electrodes.
4. The method of Claim 3 wherein there is a negative electrode and a positive electrode and wherein the negative electrode is applied proximal to the brain and the positive electrode is applied distal thereto.
5. The method of Claim 3 wherein there is a negative electrode and a positive electrode and wherein the negative electrode is placed in the vicinity of the vagus nerve and the positive electrode is applied to a remote part of the body.
6. A neurocybernetic prosthesis for controlling or preventing involuntary movements such as caused by epileptic seizures, cerebral palsy, Parkinson's disease, spasticity, motor disorders and the like comprising:  
an electrical pulse generator capable of generating pulses having a frequency of approximately between 30 and 80 cycles per second with each pulse having



-14-

a duration of between approximately .3 and 1 milli-second;

a positive electrode adapted to be applied to a person's body and means electrically connecting  
5 said electrode to said pulse generator;

a negative electrode adapted to be applied to a person's body adjacent the vagus nerve and means for connecting said electrode to said generator.

7. The invention of Claim 6 wherein said pulse generator  
10 is enclosed in a shell so that the same may be implanted in the person's body.

8. The invention of Claim 7 including means for manually turning said generator on when the same is implanted.

9. The invention of Claim 7 including means for sensing  
15 an abnormal body function and means responsive thereto for turning said pulse generator on.

10. The invention of Claim 9 wherein said sensing means senses electroencephalographic waves.

11. The invention of Claim 7 including means for  
20 varying the electrical signal generated by said generator from outside a person's body when the generator is implanted.

12. A method of controlling the output signal of  
25 a population of nerves comprising:

providing a pulse generator and a plurality of electrodes connected thereto;


applying the electrodes to the nerve population,  
and

30 varying the electrical parameters of the generator until the clinically desired nerve output signal is achieved.







*Fig. 1*




*Fig. 2*




*Fig. 3*



*Fig. 4* 2/2



*Fig. 5*




SUBSTITUTE SHEET



# INTERNATIONAL SEARCH REPORT

International Application No PCT/US84/01445

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl. 3 A61N 1/32		
U.S. Cl. 128/421		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S.	128/419C, 419E, 419R, 421, 422, 423R	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category *	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
A	US, A, 3,650,277 (Sjostrand) 21 March 1972	1-12
Y	US, A, 3,796,221 (Hagfors) 12 March 1974	2-11
Y	US, A, 3,850,161 (Liss) 26 November 1974	1, 9, 10
A	US, A, 3,918,461 (Cooper) 11 November 1975	1-12
X,Y	Journal Thoracic and Cardiovascular Surgery, Vol. 56, No. 1, issued July 1968, Aydin M. Bilgutay et al, Vagál Tuning; pages 71-82.	1-12
Y	Surgical Forum, issued 1966, Arnold Neistedt et al, 'Implantable Carotid Sinus Nerve Stimulator For Reversal of Hypertention, pages 123-127.	2-11
A	Annals of Biomedical Engineering, Vol. 8, No. 4-6, issued 1980, Tim Peters et al, 'The Principle Of Electrical Carotid... Therapy' pages 445-458.	1-12
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>15</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>1</sup>	Date of Mailing of this International Search Report <sup>2</sup>	
12 October 1984	23 OCT 1984	
International Searching Authority <sup>3</sup>	Signature of Authorized Officer <sup>10</sup>	
ISA/US		

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**